Q-omics provides the consensus-scored FAM155B profile across patient tissues and cancer cell-line models. FAM155B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, FAM155B is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, FAM155B RNA expression shows 14,750 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight OV, KIRP, and TGCT as cancer lineages where FAM155B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM155B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM155B survival associations across molecular data types. FAM155B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM155B RNA expression–survival associations across cancer types. High FAM155B expression shows unfavorable associations in STAD, LUAD and BRCA, but favorable associations in OV, PAAD and LGG. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify OV as the clearest survival context for FAM155B RNA expression.
This table summarizes FAM155B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FAM155B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM155B shows lower tumor expression in KIRC and THCA and higher tumor expression in KIRP, HNSC, LUAD and LIHC. The KIRP box plot shows higher FAM155B RNA expression in tumor versus normal tissue (log2 FC = +2.332, t-test p < 0.001).
This table shows molecular features associated with FAM155B in patient tissues and cancer cell lines. In patient samples, FAM155B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM155B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
